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• One publication reported solely on the adverse events associated with Step 2 analgesics, 15 two reported only on efficacy, 18, 19 while the rest reported on both relative efficacy and safety. 16, 17 • The most common metric for measuring effectiveness was the proportion of patients achieving at least 50% pain relief, [16] [17] [18] [19] which was used to calculate relative risk, 16 relative benefit 17 and number-needed-to-treat (Table 2) . [16] [17] [18] [19] • The most commonly reported adverse events included nausea or vomiting, drowsiness or somnolence, dizziness and headache.
16,17 Table 2 . Efficacy and safety metrics reported by publications identified in the literature review
Utility values for acute pain (Search (iii))
• Whilst the search for utility values directly for acute pain did not yield any results, one publication reporting on health utility values of chronic pain used in the place of acute pain was identified.
8
The utilities and disutilities derived from this study were based on opioid-related adverse events for chronic pain in oncology and elderly (>65 years old) patient populations in the US and Germany.
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Discussion and conclusions
Existing HE models identified in the literature
• Despite the high prevalence of acute pain, there is a lack of evidence available to inform the economic impact of this condition as demonstrated by the results of our literature review. Figure 2 depicts a graphical representation of ideal model inputs and highlights substantial data gaps in the following areas: adverse event reporting, utility values, pain control measures, discontinuation rates and resource utilisation. • In the models identified, the main drivers of cost-effectiveness were factors associated with additional contact with health care professionals, particularly given the low cost nature of many of the treatments that are widely used in acute pain treatment. Examples of these drivers include lack of pain control achieved with the treatment, treatment emergent adverse events, and the need to discontinue or swap to another treatment. Where these costs were present, they consistently and significantly outweighed the acquisition cost of the treatment under consideration.
• There was substantial variation in the assessment of clinical effectiveness, treatment-associated adverse events and time horizons in the models. Additionally only one model incorporated the results of a meta-analysis as a data input and healthcare resource use was reported in markedly different ways depending on the healthcare system.
Key data gaps identified
• The most commonly reported efficacy measurement in the literature for acute pain was the proportion of patients achieving at least 50% pain relief, which was used to calculate the number-needed-to-treat.
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While number-needed-to-treat is a useful measure for determining a treatment effect and relative efficacy of analgesics, the usefulness of this metric is limited by the pooling of data from different patient populations as the number-needed-to-treat for each analgesic was obtained from different studies of patients with acute pain in postoperative dental, gynaecologic, orthopaedic and general surgery settings. [16] [17] [18] [19] Such variability would be challenging to integrate into an economic model.
• There is therefore a need for accurate efficacy data for league tables of analgesics from patients in specific settings (e.g. specific surgical procedures, disorders with intermittent episodes of pain) and an agreement on the most appropriate efficacy measure for use in economic models.
• Other relevant and required inputs for a robust health economic model, such as medication discontinuation or use of rescue medication were not readily available in the literature. This highlights the need for robust data on why and how often patients switch or discontinue pain medication. There is also a need for literature detailing algorithms health care professionals typically follow when prescribing pain killers for acute pain.
• The generalisability of the utility values identified may be limited to the populations sampled as these scores are influenced by sociodemographic-specific cultural differences and clinical factors. Furthermore, the only publication identified reporting health utility values for acute pain assumed that chronic pain values per unit of time were equivalent to acute pain values.
• Overall, there are limited robust data available to inform HE models including consistent efficacy data available across different therapeutic options, adverse event data, utilities and disutilities and resource utilisation. There is therefore a need for research in this area to support future HE modelling and value-based treatment decision-making.
Background and objectives
Background
• Pain is a major global healthcare problem, with pain-related disorders ranking among the most common acute and chronic conditions.
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For instance, the Global Burden of Disease 2010 study found low back pain to be the most common cause of disability with acute low back pain making up 48% to 60% of the prevalence.
2
• Acute pain is defined as being short in duration (less than three months), varying in intensity, and for which the reason of onset can be attributed to a known cause such as trauma, surgery or a well-known pathological process such as myocardial infarction.
3
• Acute pain is generally responsive to analgesic treatment; however if appropriate treatment is not provided, a prolonged experience of acute pain can eventually lead to long-term changes in the central nervous system and the development of chronic pain.
4
• Furthermore, inadequate pain control and the resulting progression to chronic pain can result in substantial economic burden and have considerable implications on the cost-effective use of healthcare resources. 
Objective
• We sought to conduct a rapid review of the available literature with the aim of identifying efficacy, safety, drug and adverse event costs and utility data for the purposes of developing future health economics (HE) and budget impact models of patient outcomes and resource use for the treatment of acute pain.
Methods Electronic databases literature searches
• Three targeted literature searches were conducted in the following databases:
• EBM Reviews -Cochrane Database of Systematic Reviews • EBM Reviews -Database of Abstracts of Reviews of Effects • EBM Reviews -Health Technology Assessment • EBM Reviews -NHS Economic Evaluation Database • The searches were limited to English language and articles published up until April 2016. All retrieved publications were screened to identify:
• cost-effectiveness models for the management of acute pain (search (i))
• systematic reviews and meta-analyses reporting relative efficacy and tolerability of
Step 2 analgesics such as tramadol, tramacet, codeine or co-codamol (search (ii)) • health utility values for different pain states (search (iii))
Grey literature review
A grey literature search of internet-based resources related to acute pain was also conducted to identify additional evidence relating to cost-effectiveness studies of acute pain, systematic literature reviews and meta-analyses of Step 2 analgesics or health utilities of pain states and epidemiology data on the incidence of acute pain.
Results
The search results from the literature review are outlined in Figure 1 . • Four publications reporting on health economic models of acute pain were identified as part of the literature review (Table 1) . [6] [7] [8] [9] • The time horizons reported ranged from two days to ten days. [6] [7] [8] [9] • Efficacy was assessed using self-report pain intensity scales, visual analogue scales and measuring time without pain.
• Three models included nausea and/or vomiting as inputs in the analysis, 6, 7, 9 while two also considered central nervous system (CNS) adverse events such as drowsiness, dizziness and concentration problems. 6, 8 • The way resource use was measured varied substantially. The publication did not mention specific postoperative settings.
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